Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
Rhea-AI Summary
Alterity Therapeutics (NASDAQ:ATHE) reported a peer-reviewed NeuroImage publication from its bioMUSE study showing quantitative susceptibility mapping (QSM) MRI detects disease-specific brain iron accumulation in Multiple System Atrophy, distinguishes MSA from Parkinson’s disease, and correlates with clinical severity. Alterity is advancing ATH434 toward a pivotal Phase 3 program, with FDA End-of-Phase 2 meeting targeted for mid-2026.
AI-generated analysis. Not financial advice.
Positive
- Peer-reviewed NeuroImage publication supports QSM MRI as an objective biomarker in MSA
- QSM distinguished MSA from Parkinson’s disease with AUC 0.76–0.79 in the globus pallidus
- Higher iron content correlated with greater MSA severity on the UMSARS clinical scale
- Preliminary 12‑month data showed progressive iron accumulation paralleling clinical decline
- QSM improved diagnostic accuracy and provided evidence of ATH434 target engagement in Phase 2
- FDA Type C meetings yielded alignment on clinical pharmacology, non‑clinical, and CMC for ATH434
- End-of-Phase 2 FDA meeting for ATH434 planned for mid‑2026, preceding Phase 3
Negative
- Longitudinal QSM analysis based on a small cohort of 10 MSA patients over 12 months
- Twelve‑month progression findings described as preliminary, indicating early-stage evidence
- Pivotal Phase 3 trial of ATH434 in MSA has not yet been initiated
News Market Reaction – ATHE
On the day this news was published, ATHE gained 3.00%, reflecting a moderate positive market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $3M to the company's valuation, bringing the market cap to $89.72M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ATHE was roughly flat to slightly down (-0.21%) while biotech peers were mixed: CVM up 5%, ACET and OVID modestly positive, and OSTX down. Momentum scanner flagged ATRA and CVM moving up, reinforcing that ATHE’s move appears stock-specific rather than a sector-wide reaction.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 07 | Conference presentations | Positive | +3.3% | Announced multiple May 2026 medical conference presentations on ATH434 and MSA. |
| Apr 30 | Cash flow update | Positive | -0.4% | Quarterly cash flow and corporate update with FDA alignment and new Phase 2 analyses. |
| Apr 27 | FDA feedback | Positive | +4.8% | Received positive FDA Type C feedback on ATH434 Phase 3 CMC elements for MSA. |
| Apr 22 | Phase 2 data | Positive | -5.7% | Presented new ATH434 Phase 2 data showing slowed functional decline versus placebo. |
| Apr 17 | Board appointment | Positive | +12.6% | Appointed experienced biotech executive to board as ATH434 moves toward Phase 3. |
Recent news is largely positive, but price reactions have been mixed, with some strong rallies on corporate/strategic updates and occasional selloffs or flat trading after favorable clinical or cash-flow news.
Over the past month, Alterity has built a consistent narrative around advancing ATH434 for Multiple System Atrophy. On Apr 17, a highly experienced biotech executive joined the board, and the stock rose 12.59%. Positive Phase 2 analyses and FDA Type C feedback in late April showed supportive efficacy data and regulatory progress, yet reactions ranged from -5.66% to +4.76%. The May 7 conference update produced a modest +3.32% move. Today’s biomarker-focused publication fits into this ongoing effort to de‑risk ATH434 and refine trial design ahead of Phase 3.
Market Pulse Summary
This announcement adds a peer-reviewed validation of quantitative MRI as a biomarker in MSA, using QSM to link brain iron burden with disease severity over 12 months. It reinforces ATH434’s mechanistic rationale and trial design as the program advances toward an End-of-Phase 2 FDA meeting in mid-2026. Recent news flow has consistently highlighted Phase 2 data, regulatory alignment, and strategic preparations, while investors may watch for Phase 3 initiation and additional clinical readouts.
Key Terms
quantitative susceptibility mapping medical
biomarker medical
multiple system atrophy medical
parkinson’s disease medical
unified multiple system atrophy rating scale medical
type c meetings regulatory
phase 3 trial medical
AI-generated analysis. Not financial advice.
– Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disease-specific iron accumulation that supports diagnosis and correlates with clinical severity in patients with Multiple System Atrophy (MSA) –
– Findings support QSM as an objective imaging biomarker to enable earlier diagnosis and assess iron-modulating therapies in MSA, including Alterity’s lead candidate ATH434 –
MELBOURNE, Australia and SAN FRANCISCO, May 11, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the publication of a peer-reviewed study in NeuroImage, a leading journal in human brain imaging, demonstrating that quantitative susceptibility mapping (QSM) MRI can detect disease-specific iron accumulation in the brains of patients with Multiple System Atrophy (MSA), distinguish MSA from Parkinson’s disease, and track clinical disease severity — including in early-stage disease.
The publication, entitled “Quantitative Imaging of Iron Dysregulation in Multiple System Atrophy,” utilizes longitudinal data generated through Alterity’s Biomarkers of Progression in Multiple System Atrophy (bioMUSE) Natural History Study, together with additional cross-sectional MSA, Parkinson’s Disease (PD), and healthy control data. The study was led by investigators at Vanderbilt University Medical Center in collaboration with Alterity Therapeutics, and is available online (here).
"The bioMUSE study was designed to give us tools we could implement in our clinical program, and QSM is one of the valuable tools we identified," said David Stamler, M.D., Chief Executive Officer of Alterity. "We used this imaging approach in our Phase 2 trial of ATH434, where it improved diagnostic accuracy and provided objective evidence of target engagement. This peer-reviewed publication validates our approach and reinforces the role of QSM as a biomarker for iron-modulating therapies in MSA."
The study analyzed high-resolution structural and QSM MRI data from 10 MSA patients followed prospectively for 12 months, and cross-sectional data from 28 MSA patients, 43 PD patients, and 23 age-matched healthy controls.
Key findings include:
- Disease-specific iron accumulation. MSA patients showed significantly higher iron content in the lentiform nucleus — comprising the globus pallidus and putamen — versus both healthy controls and PD (all p<0.05), with the most pronounced effect in the globus pallidus.
- Differentiation from Parkinson’s disease. Iron content in the globus pallidus distinguished MSA from PD with moderate-to-good accuracy (AUC = 0.76–0.79), with comparable performance in the early-stage subgroup — a setting in which clinical misdiagnosis is common.
- Correlation with clinical severity. Higher iron content was significantly correlated with greater overall disease severity on the Unified Multiple System Atrophy Rating Scale (UMSARS), linking the imaging measure directly to patients’ functional and motor impairment.
- Longitudinal progression. In preliminary 12-month analyses of the early-stage bioMUSE cohort, both the magnitude and spatial extent of abnormal iron accumulation increased progressively, paralleling clinical decline.
“These data show that iron dysregulation in MSA is measurable, regionally specific, tied to clinical severity, and progressive even in early disease,” said Daniel O. Claassen, M.D., M.S., senior author of the publication, Professor of Neurology at Vanderbilt University Medical Center, and Chief Medical Advisor of Alterity. “QSM provides an objective imaging signature that can help confirm the diagnosis of MSA and connect what we see in the brain to how patients are functioning. Quantifying iron burden at the individual patient level and monitoring change over 12 months has provided important insights into MSA pathology and has led to further insights into the mechanism of ATH434. I look forward to the continued application of this technology in future clinical trials.”
Alterity continues to advance ATH434 into a Phase 3 program for MSA. The Company has received positive feedback from the U.S. Food and Drug Administration (FDA) following two recent Type C meetings, with alignment reached on clinical pharmacology and non-clinical development as well as the chemistry, manufacturing, and control (CMC) elements of the program. Alterity remains on track to hold its End-of-Phase 2 meeting with the FDA in mid-2026, the next key step toward initiation of a pivotal Phase 3 trial in MSA.
About ATH434
Alterity’s lead candidate, ATH434, is an oral agent designed to reduce iron accumulation and inhibit abnormal protein aggregation associated with neurodegeneration. ATH434 has been shown to reduce α-synuclein pathology and preserve neuronal function by restoring normal iron balance in the brain in preclinical models. As an iron chaperone, it has excellent potential to treat Parkinson’s disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). Positive results from the randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with MSA demonstrated robust clinical efficacy, target engagement as indicated by key biomarkers, and a favorable safety profile. Positive data from a second Phase 2 open-label biomarker trial in patients with more advanced MSA reinforced these results. ATH434 has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), and Orphan Drug Designation by the FDA and the European Commission for the treatment of MSA.
About bioMUSE
Biomarkers of progression in Multiple System Atrophy (bioMUSE) is a natural history study that aims to track the progression of individuals with MSA, a parkinsonian disorder without an approved therapy. The study is being conducted in collaboration with Vanderbilt University Medical Center in the U.S. under the direction of Daniel Claassen, M.D., M.S., Professor of Neurology and Principal Investigator. Natural history studies are important for characterizing disease progression in selected patient populations. The study has provided rich data for optimizing the design of Alterity’s randomized ATH434-201 Phase 2 clinical trial and enrolled approximately 20 individuals with clinically probable or clinically established MSA. BioMUSE continues to provide vital information on early stage MSA patients, informs the selection of biomarkers suitable to evaluate target engagement and preliminary efficacy, and delivers clinical data to characterize disease progression in a patient population that mirrors those currently enrolling in the Phase 2 clinical trial.
About Multiple System Atrophy
Multiple System Atrophy (MSA) is a rare, neurodegenerative disease characterized by failure of the autonomic nervous system and impaired movement. The symptoms reflect the progressive loss of function and death of different types of nerve cells in the brain and spinal cord. It is a rapidly progressive disease and causes profound disability. MSA is a Parkinsonian disorder characterized by a variable combination of slowed movement and/or rigidity, autonomic instability that affects involuntary functions such as blood pressure maintenance and bladder control, and impaired balance and/or coordination that predisposes to falls. A pathological hallmark of MSA is the accumulation of the protein α-synuclein within glia, the support cells of the central nervous system, and neuron loss in multiple brain regions. MSA affects up to 50,000 individuals in the U.S., and while some of the symptoms of MSA can be treated with medications, currently there are no drugs that are able to slow disease progression and there is no cure.1
1Multiple System Atrophy | National Institute of Neurological Disorders and Stroke (nih.gov)
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at https://alteritytx.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Contacts:
Investors:
Elyse Shapiro
ir@alteritytx.com
Remy Bernarda
Investor Relations Advisory Solutions
ir@alteritytx.com
+1 (415) 203-6386
Media
Casey McDonald
Tiberend Strategic Advisors, Inc.
cmcdonald@tiberend.com
+1 (646) 577-8520
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.
Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
